XML 16 R5.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Condensed Statements of Changes in Stockholders' Deficit - USD ($)
$ in Thousands
Total
Public Equity Offering - ATM
Public Equity Offering
Common Stock
Common Stock
Public Equity Offering - ATM
Common Stock
Public Equity Offering
Additional Paid-in Capital
Additional Paid-in Capital
Public Equity Offering - ATM
Additional Paid-in Capital
Public Equity Offering
Accumulated Deficit
Beginning balance (in shares) at Dec. 31, 2022       54,827,734            
Beginning balance at Dec. 31, 2022 $ (118,554)     $ 55     $ 192,598     $ (311,207)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                    
Common Stock issued under public equity offering (in shares)       1,078,622            
Common Stock issued under public equity offering-ATM 993     $ 1     992      
Costs of common stock issued under public equity offering-ATM (77)           (77)      
Share-based compensation expense 344           344      
Vested restricted stock units (in shares)       16,005            
Vested restricted stock units (8)           (8)      
Other (1)           (1)      
Net (loss) income 8,068                 8,068
Ending balance (in shares) at Mar. 31, 2023       55,922,361            
Ending balance at Mar. 31, 2023 (109,235)     $ 56     193,848     (303,139)
Beginning balance (in shares) at Dec. 31, 2022       54,827,734            
Beginning balance at Dec. 31, 2022 (118,554)     $ 55     192,598     (311,207)
Ending balance (in shares) at Dec. 31, 2023       68,533,085            
Ending balance at Dec. 31, 2023 (106,487)     $ 69     212,521     (319,077)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                    
Common Stock issued under public equity offering (in shares)         4,557,220 16,666,667        
Common Stock issued under public equity offering-ATM   $ 12,385 $ 75,000   $ 4 $ 17   $ 12,381 $ 74,983  
Costs of common stock issued under public equity offering-ATM   $ (410) $ (5,187)         $ (410) $ (5,187)  
Share-based compensation expense 1,580           1,580      
Vested restricted stock units (in shares)       490,359            
Vested restricted stock units $ (893)           (893)      
Options exercises, net (in shares) 231,400                  
Options exercised, net $ 539                  
Net (loss) income (12,828)                 (12,828)
Ending balance (in shares) at Mar. 31, 2024       90,478,731            
Ending balance at Mar. 31, 2024 $ (36,301)     $ 90     $ 295,514     $ (331,905)